Transcriptomic study of dormant gastrointestinal cancer stem cells

International Journal of Oncology

Volumn 41, Issue 3, 2012, Pages 979-984

  Nishikawa, Shimpei ^a   Dewi, Dyah Laksmi ^a   Ishii, Hideshi ^a   Konno, Masamitsu ^a   Haraguchi, Naotsugu ^a   Kano, Yoshihiro ^a   Fukusumi, Takahito ^a   Ohta, Katsuya ^a   Noguchi, Yuko ^a   Ozaki, Miyuki ^a   Sakai, Daisuke ^a   Satoh, Taroh ^a   Doki, Yuichiro ^a   Mori, Masaki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer stem cells; Chemotherapy; Dormancy; Transcriptome

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; MICRORNA 101; MICROSOMAL AMINOPEPTIDASE; PROTEIN P53; THY 1 ANTIGEN; TRANSCRIPTION FACTOR EZH2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DNA DAMAGE; DORMANCY; DRUG SENSITIVITY; EPIGENETICS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHARMACOGENOMICS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS;

ANOXIA; ANTIGENS, CD13; ANTIGENS, THY-1; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION PROFILING; HUMANS; MICRORNAS; NEOPLASTIC STEM CELLS; OXIDATIVE STRESS; TRANSCRIPTOME;

EID: 84864994093     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1531     Document Type: Article

References (25)

1. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001. (Pubitemid 33041634)
2. Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 10: 755-768, 2008.
3. Dewi DL, Ishii H, Kano Y, et al: Cancer stem cell theory in gastrointestinal malignancies: recent progress and upcoming challenges. J Gastroenterol 46: 1145-1157, 2011.
4. Li L and Clevers H: Coexistence of quiescent and active adult stem cells in mammals. Science 327: 542-545, 2010.
5. Haraguchi N, Ishii H, Mimori K, et al: CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 120: 3326-3339, 2010.
6. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K and Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73: 39-85, 2004. (Pubitemid 39050363)
7. Nishikawa S, Ishii H, Haraguchi N, et al: Genotoxic therapy stimulates error-prone DNA repair in dormant hepatocellular cancer stem cells. Exp Ther Med (In press).
8. Haraguchi N, Ishii H, Nagano H, Doki Y and Mori M: The future prospects and subject of the liver cancer stem cells study for the clinical application. Gastroenterology: Feb 23, 2011 (Epub ahead of print).
9. Kim HM, Haraguchi N, Ishii H, et al: Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon. Ann Surg Oncol: Aug 31, 2011 (Epub ahead of print).
10. + cancer stem cells in human liver cancer. Cancer Cell 13: 153-166, 2008.
11. Weinstock DM, Richardson CA, Elliott B and Jasin M: Modeling oncogenic translocations: distinct roles for double-strand break repair pathways in translocation formation in mammalian cells. DNA Repair (Amst) 5: 1065-1074, 2006. (Pubitemid 44291619)
12. Ishii H, Iwatsuki M, Ieta K, Ohta D, Haraguchi N, Mimori K and Mori M: Cancer stem cells and chemoradiation resistance. Cancer Sci 99: 1871-1877, 2008.
13. Chen H, Rossier C and Antonarakis SE: Cloning of a human homolog of the Drosophila enhancer of zeste gene (EZH2) that maps to chromosome 21q22.2. Genomics 38: 30-37, 1996. (Pubitemid 26423910)
14. Varambally S, Cao Q, Mani RS, et al: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322: 1695-1699, 2008.
15. Friedman JM, Liang G, Liu CC, et al: The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 69: 2623-2629, 2009.
16. Cao P, Deng Z, Wan M, Huang W, et al: MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer 9: 108, 2010.
17. Wang HJ, Ruan HJ, He XJ, et al: MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer 46: 2295-2303, 2010.
18. Bao B, Ali S, Banerjee S, Wang Z, et al: Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 72: 335-345, 2012.
19. Zhang JG, Guo JF, Liu DL, Liu Q and Wang JJ: MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol 6: 671-678, 2011.
20. Smits M, Nilsson J, Mir SE, et al: miR-101 is downregulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 1: 710-720, 2010.
21. Banerjee R, Mani RS, Russo N, et al: The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene 30: 4339-4349, 2011.
22. Moskwa P, Buffa FM, Pan Y, et al: miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 41: 210-220, 2011.
23. Liu Z, Liu J, Segura MF, et al: MiR182 overexpression in tumorigenesis of high-grade ovarian papillary serous carcinoma. J Pathol: Feb 9, 2012 (Epub ahead of print).
24. Segura MF, Hanniford D, Menendez S, et al: Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA 106: 1814-1819, 2009.
25. Dewi DL, Ishii H, Haraguchi N, et al: Reprogramming of gastrointestinal cancer cells. Cancer Sci 103: 393-399, 2012.